Favorable Palliative Effect of 177 Lu-FAPI-2286 in Two Breast Cancer Patients With Refractory Bone Pains.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40394843.
- Also identified by DOI 10.1097/RLU.0000000000005753.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We present 2 women with advanced invasive ductal carcinoma who developed skeletal metastases despite extensive treatment, including surgery, chemotherapy, and hormonal therapy. Both patients experienced debilitating pain and were evaluated for bone palliation therapy using 177 Lu-FAPI-2286, after 99m Tc-FAPI-46 scintigraphy showed suitable uptake. Remarkably, both patients reported significant pain relief shortly after treatment. The only adverse effect noted was grade III thrombocytopenia in 1 patient. These cases highlight the potential of 177 Lu-FAPI-2286 in providing rapid and effective palliation for breast cancer patients suffering from refractory pain, suggesting further investigation into its role in theranostics and palliative care. In this report, we also conducted a comprehensive literature review on radio-ligand therapy with 177 Lu-FAPI in breast cancer.
Medical subject headings
- Bone Neoplasms
- Breast Neoplasms
- Lutetium
- Pain
- Palliative Care